Journal of the National Cancer Center

The Journal of the National Cancer Center (JNCC) is a peer-reviewed, fully open-access oncology journal sponsored by the National Cancer Center of China and published by Elsevier, launched in March 2021, covering all areas of cancer research, with a 2025 Journal Impact Factor of 25.2《国家癌症中心杂志》（JNCC）是由中国国家癌症中心（National Cancer Center）主办、爱思唯尔（Elsevier）出版的同行评审全开放获取肿瘤学期刊，2021 年 3 月创刊，涵盖癌症研究的各个领域，2025 年影响因子为 25.2。

Scope

• It publishes original research, reviews, commentaries, brief communications, correspondences and editorials across all areas of cancer research该刊刊载原创研究、综述、评论、简报、通讯与社论，覆盖癌症研究的各个领域。
• It promotes studies that answer fundamental questions of cancer biology and epidemiology该刊推动解答癌症生物学与流行病学基本问题的研究。
• It facilitates state-of-the-art approaches for cancer prevention, detection, diagnosis and treatment该刊促进癌症预防、检测、诊断与治疗的前沿方法。
• It places emphasis on the international aspects of cancer prevention and control该刊重视癌症预防与控制领域的国际化议题。
• It particularly encourages randomized controlled clinical trials and provides them with expedited review该刊尤其鼓励随机对照临床试验，并为其提供加急评审。
• It applies statistical review to any manuscript reporting quantitative research findings该刊对任何报告定量研究结果的稿件实施统计学评审。
• Manuscripts identified by the editorial board as top priority are fast-tracked and published online within eight weeks被编辑委员会评为最高优先级的稿件将走快速通道，在八周内在线发表。
• It is fully open access, with an article publishing charge of USD 2,700该刊为全开放获取，文章处理费为 2700 美元。

History

• It was launched in March 2021 by the National Cancer Center of China, and the inaugural editorial was written by Jie He该刊由中国国家癌症中心于 2021 年 3 月创办，创刊社论由赫捷（Jie He）撰写。^[1]
• It is published by Elsevier on behalf of the Chinese National Cancer Center, which owns the title该刊由爱思唯尔（Elsevier）代表中国国家癌症中心出版，刊名归该中心所有。
• It is supervised by the National Health Commission of China and sponsored by the National Cancer Center该刊由中国国家卫生健康委员会主管、国家癌症中心主办。
• Its early issues carried the national cancer statistics of China, establishing it as a key venue for Chinese cancer epidemiology其早期各期刊载中国全国癌症统计数据，使其成为中国癌症流行病学的重要发表平台。^[2]
• It now publishes quarterly and is indexed in the Emerging Sources Citation Index该刊现按季出版，并已收录于新兴来源引文索引（ESCI）。
• Its 2025 Journal Impact Factor is 25.2, ranking 13th of 333 journals in the oncology category其 2025 年影响因子为 25.2，在肿瘤学类别的 333 种期刊中排名第 13 位。

Editors

• The editor-in-chief is Jie He, MD, who wrote the journal's inaugural editorial and leads its editorial board现任主编为赫捷（Jie He），他撰写了该刊创刊社论并领导其编辑委员会。
• He works in the Department of Thoracic Surgery at the National Cancer Center and the Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College他供职于中国国家癌症中心胸外科，以及中国医学科学院与北京协和医学院肿瘤医院。
• The editorial board is committed to rigorous yet rapid review, with top-priority manuscripts published online within eight weeks编辑委员会致力于严谨而快速的评审，最高优先级的稿件在八周内在线发表。
• Statistical review is applied to any manuscript that reports quantitative research findings对任何报告定量研究结果的稿件都会实施统计学评审。
• The median time from submission to first decision is 1 day, and the median time from submission to acceptance is 141 days从投稿到初审决定的中位时间为 1 天，从投稿到接收的中位时间为 141 天。
• The journal invites submissions from the international cancer research community and provides expedited handling of clinical trials该刊面向国际癌症研究界征稿，并对临床试验提供加急处理。